Does an interferon-gamma release assay change practice in possible latent tuberculosis?

Tiernan, James; Gilhooley, S; Jones, Michael E.; Chalmers, James D.; McSparron, Ceri; Laurenson, Ian F.; Hill, Adam T.

doi:10.1093/qjmed/hcs185

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the majority of other studies, greater diff erence between QFT-GIT and TST results has been documented 2,5,[15][16][17] . Such a diff erence, which favors QFT-GIT test performance, appears to be due to the falsepositive TST results because of previous BCG immunization and due to false-negative TST results in immunocompromised patients 2,5,[15][16][17] .…”

Section: Discussionmentioning

confidence: 93%

“…Such a diff erence, which favors QFT-GIT test performance, appears to be due to the falsepositive TST results because of previous BCG immunization and due to false-negative TST results in immunocompromised patients 2,5,[15][16][17] . In this study, the prevalence of the history of tuberculosis contact was signifi cantly higher in the study group as compared with the control group (30%:10%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists

Baričević

Grle

Vergles

et al. 2017

acc

View full text Add to dashboard Cite

SUMMARY -Th e aim of this study was to investigate the role of the QuantiFERON-TB Gold In-Tube test (QFT-GIT) in detecting latent tuberculosis in immunocompromised patients before introducing tumor necrosis factor (TNF-α) antagonists. Th e study included 300 subjects of similar age. Th e study group comprised of 150 QuantiFERON (QFT) positive subjects with rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, while control group comprised of 150 QFT negative respondents with the same diseases. Exhaustive medical history was documented for all patients. Screening tests were performed including QFT-GIT, tuberculin skin test (TST), chest radiography and detection of Mycobacterium tuberculosis in sputum culture 2 times. A positive QFT-GIT test result, regardless of TST result, was considered as an indication for latent tuberculosis infection (LTBI) treatment. Results of this study showed good correlation between the conclusive results of QFT-GIT and TST. All study group patients had normal clinical fi ndings, normal radiologic fi ndings and negative results of sputum microbiological analysis during the course of prophylaxis and after its completion and during the course of biological therapy. Conversion of positive QFT-GIT test to negative was observed in 4% of study group patients, while QFT negative respondents remained negative. Th ere was a statistically signifi cant positive correlation between QFT-GIT, TST results and patient age, smoking habit and contact with tuberculosis. Study results showed that along with good clinical evaluation and detailed medical history, it is important to conduct testing in order to avoid disease progression or unnecessary isoniazid prophylaxis.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists

Baričević

Grle

Vergles

et al. 2017

acc

View full text Add to dashboard Cite

show abstract

“…Tiernan et al [100] reported the changes in the clinical practice for the diagnosis of latent tuberculosis infection (LTBI) with interferon-gamma release assay, namely, QuantiFERON-TB Gold In-Tube (QFT, Cellestis, Australia). Unfortunately, the reported outcome was limited to the number of changes in practice due to QFT as absolute frequency and percentages [100].…”

Section: Cost-benefit Analysismentioning

confidence: 99%

Medical Diagnostic Tests: A Review of Test Anatomy, Phases, and Statistical Treatment of Data

Bolboacă

2019

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Diagnostic tests are approaches used in clinical practice to identify with high accuracy the disease of a particular patient and thus to provide early and proper treatment. Reporting high-quality results of diagnostic tests, for both basic and advanced methods, is solely the responsibility of the authors. Despite the existence of recommendation and standards regarding the content or format of statistical aspects, the quality of what and how the statistic is reported when a diagnostic test is assessed varied from excellent to very poor. This article briefly reviews the steps in the evaluation of a diagnostic test from the anatomy, to the role in clinical practice, and to the statistical methods used to show their performances. The statistical approaches are linked with the phase, clinical question, and objective and are accompanied by examples. More details are provided for phase I and II studies while the statistical treatment of phase III and IV is just briefly presented. Several free online resources useful in the calculation of some statistics are also given.

show abstract

“…Research shows that the physicians' education and experience both influence their decision-making process, including their adherence to practice guidelines [13,[33][34][35] . Empirical findings on test adoption by physicians highlight specific issues to consider while introducing such innovations [36][37][38][39] . The development of a predictive test through PD building on the physician's experience and involving them in evidence-based medicine is likely to encourage them to incorporate this tool into their practice.…”

Section: Clinical Decision Makingmentioning

confidence: 99%

Exploring the Use of a Participative Design in the Early Development of a Predictive Test: The Importance of Physician Involvement

Veilleux

Villeneuve²,

Lachapelle³

et al. 2017

Public Health Genomics

View full text Add to dashboard Cite

In this study, we contribute to the personalized medicine and health care management literature by developing and testing a new participative design approach. We propose that involving gastroenterologists in the development of a predictive test to assist them in their clinical decision-making process for the treatment of inflammatory bowel diseases will increase the likelihood of their acceptance of the innovation. Based on data obtained from 6 focus groups across Canada from a total of 28 physicians, analyses reveal that current tools do not enable discriminating between treatment options to find the best fit for each patient. Physicians expect a new predictive tool to have the capability of showing clear reliability and significant benefits for the patient, while being accessible in a timely manner that facilitates clinical decisions. Physicians also insist on their key role in the implementation process, hence confirming the relevance and importance of participative designs in personalized medicine.

show abstract

Does an interferon-gamma release assay change practice in possible latent tuberculosis?

Abstract: This study demonstrates a significant change of clinical practice due to IGRA use. Our findings support the NICE 2011 recommendations.

Cited by 4 publications

References 8 publications

QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists

QuantiFERON-TB Gold In-Tube Test in the Diagnosis of Latent Tuberculosis Infection in Arthritis Patients Treated with Tumor Necrosis Factor Antagonists

Medical Diagnostic Tests: A Review of Test Anatomy, Phases, and Statistical Treatment of Data

Exploring the Use of a Participative Design in the Early Development of a Predictive Test: The Importance of Physician Involvement

Contact Info

Product

Resources

About